Skip to main content
HHS $4.30 +53.02%
HHS logo

HHS · Harte Hanks Inc

Track HHS — free
$4.30 +1.49 (+53.02%) At close · Aug 14
Market Cap
$31.90M
Shares
7.45M
All earnings calls

Earnings call · FY2023 Q4

Harte Hanks Inc Q4 FY2023 Earnings Call

Harte Hanks Inc Q4 FY2023 Earnings Call

Concluded Mar 14, 2024
Mar 14, 2024 16 turns
Period
FY2023 Q4
Runtime
Sources
3 artifacts

Executive readout · one minute

Call research workspace

Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.

Sales and Marketing Overhaul / Go-to-Market Strategy 18 Project Elevate Transformation 15 Cost Reduction Initiative 12 Segment Performance and Outlook 11 Customer Pipeline and Sales Cycle Risks 10 International Expansion 8

Management tone

Confident

Net tone +65 · low hedging

Grounding quotes
  • “we're executing on our commitments. Project Elevate, while challenging, has been a unifying endeavor thus far for our senior leadership team. And the leading indicators, albeit early, are very encouraging”
  • “I'm confident that we will experience a growth year and a rebound in our sales services”

Research coverage

3 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $49.49M -9.7% YoY
Net income · derived Q4 -$1.98M -109.1% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document